EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study

R Rivera-Díaz, T Pozo, F Alfageme, B Díaz Ley, G F Osorio, R Chico, E Vilarrasa, C Silvente, C Ciudad Blanco, J Romaní, A Martorell, P Fernández und 2 weitere

Actas Dermo-Sifiliográficas · 2023

DOI: 10.1016/j.ad.2023.06.013 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Actas Dermo-Sifiliográficas, 2023. Verfasst von R Rivera-Díaz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain. Electronic address: rriveradiaz@hotmail.com. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic skin condition causing lesions in which high levels of interleukin (IL)-23 and T-helper 17 cells are found. Adalimumab remains the only approved treatment. Guselkumab, an antibody targeting the p19 protein subunit of extracellular IL-23, is approved for the treatment of moderate-severe psoriasis, but evidence on its efficacy in treating HS is limited. OBJECTIVES: To assess the effectiveness and safety of guselkumab in treating moderate-severe HS under clinical practice conditions. METHODS: A multicentre retrospective observational study was carried out in 13 Spanish Hospitals including adult HS patients treated with guselkumab within a compassionate use programme (March 2020-March 2022). Data referred to patient demographic and clinical characteristics at treatment initiation (baseline), patient-reported outcomes (Numerical Pain Rating Scale [NPRS] and Dermatology Life Quality Index [DLQI]), physician scores (International Hidradenitis Suppurativa Severity Score System [IHS4], HS Physical Global Score [HS-PGA] and Hidradenitis Suppurativa Clinical Response [HiSCR]) were recorded at baseline and at 16, 24, and 48 weeks of treatment. RESULTS: A total of 69 patients were included. Most (84.10%) had severe HS (Hurley III) and had been diagnosed for over ten years (58.80%). The patients had been subjected to multiple non-biological (mean 3.56) or biological (mean 1.78) therapies, and almost 90% of those treated with biologics had received adalimumab. A significant decrease in IHS4, HS-PGA, NPRS, and DLQI scores was observed from baseline to 48 weeks of guselkumab treatment (all p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaBiological ProductsAdultHumansAdalimumabRetrospective StudiesSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

BiologicsBiológicosEvidencia del mundo realGuselkumabHidradenitis suppurativaHidradenitis supurativaReal-world evidence

Substanzen

AdalimumabBiological ProductsguselkumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain. Electronic address: rriveradiaz@hotmail.com.
  • Department of Dermatology, Hospital Rio Hortega, Valladolid, Spain.
  • Department of Dermatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario del Sureste, Arganda, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain.
  • Department of Dermatology, Hospital Infanta Sofía, Alcobendas, Madrid, Spain.

Zitieren

APA

Rivera-Díaz, R., Pozo, T., Alfageme, F., Díaz Ley, B., Osorio, G. F., Chico, R., Vilarrasa, E., Silvente, C., Ciudad Blanco, C., Romaní, J., Martorell, A., Fernández, P., Romero Ferreiro, C., & Molina Leyva, A. (2023). The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2023.06.013

Vancouver

Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, et al. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Actas Dermo-Sifiliográficas. 2023. doi:10.1016/j.ad.2023.06.013

BibTeX
@article{RiveraDaz2023,
  author = {Rivera-Díaz, R and Pozo, T and Alfageme, F and Díaz Ley, B and Osorio, G F and Chico, R and Vilarrasa, E and Silvente, C and Ciudad Blanco, C and Romaní, J and Martorell, A and Fernández, P and Romero Ferreiro, C and Molina Leyva, A},
  title = {The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2023},
  doi = {10.1016/j.ad.2023.06.013}
}
Kostenlos starten →